ReviewNature reviews. Clinical oncology2017
The landscape of new drugs in lymphoma.
Review in Nature reviews. Clinical oncology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.
- International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).Annals of oncology : official journal of the European Society for Medical Oncology · 2017Guideline
- Zanubrutinib-based regimen as the salvage or bridging treatment of CART therapy in relapsed or refractory, non-germinal center B-cell-like diffuse large B-cell lymphoma: a retrospective multicenter cohort study.Frontiers in immunology · 2026Observational
- In Silico Drug Repurposing Against PSMB8 as a Potential Target for Acute Myeloid Leukemia Treatment.Molecular biotechnology · 2025Article
- Circulating tumor DNA in lymphoma: technologies and applications.Journal of hematology & oncology · 2025Review
- Global, regional and national temporal trends in incidence and mortality of non-Hodgkin lymphoma from 1992 to 2021: an age-period-cohort analysis.Annals of hematology · 2025Article
- Development of patient-derived lymphomoids with preserved tumor architecture for lymphoma therapy screening.Nature communications · 2024Article
- A first-in-class Wiskott-Aldrich syndrome protein activator with antitumor activity in hematologic cancers.Haematologica · 2024Article
- Insight into Mantle Cell Lymphoma Pathobiology, Diagnosis, and Treatment Using Network-Based and Drug-Repurposing Approaches.International journal of molecular sciences · 2024Article
- Programmed Death Ligand 1 (PD-L1) Expression in Lymphomas: State of the Art.International journal of molecular sciences · 2024Review
- Plant-derived vesicle-like nanoparticles: A new tool for inflammatory bowel disease and colitis-associated cancer treatment.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Review
- Article
- Opportunities and challenges for anti-CD47 antibodies in hematological malignancies.Frontiers in immunology · 2024Review
- Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma.Blood advances · 2022Article
- The novel LSD1 inhibitor ZY0511 suppresses diffuse large B-cell lymphoma proliferation by inducing apoptosis and autophagy.Medical oncology (Northwood, London, England) · 2021Article
- Review
- Engaging the Innate and Adaptive Antitumor Immune Response in Lymphoma.International journal of molecular sciences · 2021Review
- Gut Microbiota in Untreated Diffuse Large B Cell Lymphoma Patients.Frontiers in microbiology · 2021Article
- Successful Management of a Patient with Refractory Primary Central Nervous System Lymphoma by Zanubrutinib.OncoTargets and therapy · 2021Article
- Risk-adapted therapy in follicular lymphoma: Is it time to "FLEX"?American journal of hematology · 2020Article
- Genetic aberrations ofEJHaem · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 14 institutions in 6 countries.
Funding
Abstract
The landscape of drugs for the treatment of lymphoma has become crowded in light of the plethora of new agents, necessitating the efficient prioritization of drugs for expedited development. The number of drugs available, and the fact that many can be given for an extended period of time, has resulted in the emergence of new challenges; these include determining the optimal duration of therapy, and the need to balance costs, benefits, and the risk of late-onset toxicities. Moreover, with the increase in the number of available investigational drugs, the number of possible combinations is becoming overwhelming, which necessitates prioritization plans for the selective development of novel combination regimens. In this Review, we describe the most-promising agents in clinical development for the treatment of lymphoma, and provide expert opinion on new strategies that might enable more streamlined drug development. We also address new approaches for patient selection and for incorporating new end points into clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.